Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

Study:

A Long-Term Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

Rationale:

n/a

Purpose:

This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician`s standard practice and discretion.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Rheumatoid Arthritis n/a Phase 4

Verified by Genentech September, 2013

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00443443

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Swati Tole, M.D., M.S.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site